Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | REV1 | Q9UBZ9 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278718 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KDM4ETHRBSMN1; SMN2KMT2A | |
| SCHEMBL5754633 | 0.85 | ALDH1A1 (0.72) | ALDH1A1KDM4ETHRBATMLMNA | |
| SCHEMBL7278994 | 0.85 | SMN1; SMN2 (0.73) | ALDH1A1KDM4ETHRBATMLMNA | |
| SCHEMBL1441662 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KDM4ETHRBATMLMNA | |
| SCHEMBL7282287 | 0.85 | NPC1 (0.58) | ALDH1A1KDM4ETHRBATMLMNA | |
| SCHEMBL793647 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KDM4ETHRBLMNAHTT | |
| SCHEMBL7282020 | 0.84 | CA1 (0.58) | ALDH1A1KDM4ETHRBATMLMNA | |
| Hydrochloric Acid SCHEMBL210978 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KDM4ETHRBLMNAHTT | |
| SCHEMBL7279123 | 0.81 | KHK (0.53) | ALDH1A1KDM4ETHRBATMLMNA | |
| SCHEMBL7288853 | 0.81 | ALDH1A1 (0.71) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247761-A1 | SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF AUTOIMMUNE, INFLAMMATION OR INFECTION RELATED DISORDERS | TAIWANJ PHARMACEUTICALS CO., LTD (TW) | 2020-08-06 | — | — | US | disclosed |
| CN-105418506-B | Acetobenzylamide piperazine derivative and its application as neuroprotection agent | 上海医药工业研究院 | 2018-04-24 | — | — | CN | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| CN-1310709-A | N, N-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247761-A1 | SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF AUTOIMMUNE, INFLAMMATION OR INFECTION RELATED DISORDERS | TLR4, TLR1, TLR5 | ALDH1A1 3965/4885KDM4E 555/4885THRB 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.